HUP0002495A1 - Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use - Google Patents

Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use

Info

Publication number
HUP0002495A1
HUP0002495A1 HU0002495A HUP0002495A HUP0002495A1 HU P0002495 A1 HUP0002495 A1 HU P0002495A1 HU 0002495 A HU0002495 A HU 0002495A HU P0002495 A HUP0002495 A HU P0002495A HU P0002495 A1 HUP0002495 A1 HU P0002495A1
Authority
HU
Hungary
Prior art keywords
group
optionally substituted
vla
cycloalkyl
aryl
Prior art date
Application number
HU0002495A
Other languages
Hungarian (hu)
Inventor
Michael S. Dappen
Darren B. Dressen
Francine S. Grant
Louis John Lombardo
Michael A. Pleiss
Christopher M. Semko
Eugene D. Thorsett
Original Assignee
American Home Products Corp.
Elan Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp., Elan Pharmaceuticals, Inc. filed Critical American Home Products Corp.
Publication of HUP0002495A1 publication Critical patent/HUP0002495A1/en
Publication of HUP0002495A3 publication Critical patent/HUP0002495A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A találmány tárgya (I) és (IA) általános képletű vegyületekgyógyászati szempontból elfogadható sóik, és ezeket tartalmazógyógyászati készítmények. A képletekben R1 jelentése adott esetbenszubsztituált alkil-, aril-, cikloalkil-, heterociklusos- ésheteroarilcsoport; R2 jelentése hidrogénatom, adott esetbenszubsztituált alkil-, cikloalkil-, cikloalkenil-, heterociklusos-,aril- és heteroarilcsoport; vagy R1 és R2 jelentése a kapcsolódóatomokkal együtt adott esetben szubsztituált heterociklusoscsoport; R3jelentése hidrogénatom, adott esetben szubsztituált alkil-,cikloalkil-, aril-, heteroarilcsoport és heterociklusos csoport; vagyR2 és R3 jelentése a kapcsolódó atomokkal együtt adott esetbenszubsztituált telített heterociklusos csoport; R5 jelentése -ALK-Xvagy =CH2-Y általános képletű csoport; R6 jelentése 2,4-dioxo-tetrahidrofurán-3-yl(3,4-enol)-, amino-, alkoxi-, szubsztituáltalkoxi-, cikloalkoxi-, szubsztituált cikloalkoxi-, -O-(N-szukcinimidil)-, -NH-adamantil-, -O-koleszt-5-en-3-b-il- csoport, -NHOY általános képletű csoport; Q jelentése -C(X)NR7- általánosképletű csoport, ahol R7 jelentése hidrogénatom vagy alkilcsoport és Xjelentése oxigénatom vagy kénatom. A találmány szerinti vegyületekalkalmasak VLA-4 által közvetített gyulladásos megbetegedésekkezelésére. ÓThe subject of the invention is compounds of formulas (I) and (IA), their pharmaceutically acceptable salts, and pharmaceutical preparations containing them. In the formulas, R1 is an optionally substituted alkyl, aryl, cycloalkyl, heterocyclic and heteroaryl group; R 2 is a hydrogen atom, an optionally substituted alkyl, cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl group; or R1 and R2 together with the attached atoms are optionally substituted heterocyclic groups; R3 is a hydrogen atom, optionally substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic groups; or R 2 and R 3 together with the attached atoms are optionally substituted saturated heterocyclic groups; R5 is a group of the general formula -ALK-X or =CH2-Y; R6 is 2,4-dioxo-tetrahydrofuran-3-yl(3,4-enol)-, amino-, alkoxy-, substituted-alkoxy-, cycloalkoxy-, substituted cycloalkoxy-, -O-(N-succinimidyl)-, -NH -adamantyl-, -O-cholest-5-en-3-b-yl- group, -NHOY group; Q is a group of the general formula -C(X)NR7-, where R7 is a hydrogen atom or an alkyl group and X is an oxygen atom or a sulfur atom. The compounds according to the invention are suitable for the treatment of inflammatory diseases mediated by VLA-4. HE

HU0002495A 1997-07-31 1998-07-31 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use HUP0002495A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90441797A 1997-07-31 1997-07-31

Publications (2)

Publication Number Publication Date
HUP0002495A1 true HUP0002495A1 (en) 2000-12-28
HUP0002495A3 HUP0002495A3 (en) 2001-01-29

Family

ID=25419120

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002495A HUP0002495A3 (en) 1997-07-31 1998-07-31 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use

Country Status (12)

Country Link
EP (1) EP1001971A1 (en)
JP (1) JP2001512135A (en)
KR (1) KR20010022406A (en)
CN (1) CN1265670A (en)
AU (1) AU8585098A (en)
BR (1) BR9812111A (en)
CA (1) CA2290749A1 (en)
HU (1) HUP0002495A3 (en)
IL (1) IL133639A0 (en)
NO (1) NO20000410L (en)
PL (1) PL338373A1 (en)
WO (1) WO1999006432A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6093696A (en) * 1997-05-30 2000-07-25 Celltech Therapeutics, Limited Tyrosine derivatives
AU8163398A (en) 1997-06-23 1999-01-04 Pharmacia & Upjohn Company Inhibitors of alpha4beta1mediated cell adhesion
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
AU751950B2 (en) * 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1056714B1 (en) 1998-02-26 2004-08-11 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
AR035476A1 (en) 1999-01-22 2004-06-02 Elan Pharm Inc HETEROARILO AND HETEROCICLIC COMPOUNDS WITH FUSIONED RING, WHICH INHIBIT THE ADHESION OF LEUKOCYTES THROUGH VLA-4, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A BIOLOGICAL METHOD 4
CA2359115C (en) 1999-01-22 2011-06-21 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1144435B1 (en) * 1999-01-26 2006-04-12 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
SK287075B6 (en) * 1999-08-13 2009-11-05 Biogen Idec Ma Inc. Cell adhesion inhibitors and pharmaceutical compositions comprising them
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
OA12126A (en) 1999-12-28 2006-05-05 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune,and respiratory diseases.
AU2001248553A1 (en) 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6740654B2 (en) 2000-07-07 2004-05-25 Celltech R & D Limited Squaric acid derivatives
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2005022976A (en) * 2001-07-18 2005-01-27 Ajinomoto Co Inc Carboxylic acid derivative
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
ES2197003B1 (en) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. NEW ANTAGONIST COMPOUNDS OF INTEGRINAS ALFA.
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
PL2288715T3 (en) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Human serum albumin linkers and conjugates thereof
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
CA3019130A1 (en) * 2016-04-01 2017-10-05 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
CN109516925B (en) * 2018-10-31 2021-07-16 陕西慧康生物科技有限责任公司 Synthesis method of glutamic acid-1-methyl ester-5-tert-butyl ester
CN114605348B (en) * 2022-05-12 2022-08-16 北京鑫开元医药科技有限公司 Compounds having HDAC inhibitory activity, preparation method, compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH0873422A (en) * 1994-09-07 1996-03-19 Kdk Corp New amino acid ester and method for detecting leukocyte, esterase or protease
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
KR20010022406A (en) 2001-03-15
AU8585098A (en) 1999-02-22
NO20000410D0 (en) 2000-01-27
NO20000410L (en) 2000-03-28
HUP0002495A3 (en) 2001-01-29
IL133639A0 (en) 2001-04-30
BR9812111A (en) 2000-07-18
CA2290749A1 (en) 1999-02-11
CN1265670A (en) 2000-09-06
EP1001971A1 (en) 2000-05-24
WO1999006432A1 (en) 1999-02-11
JP2001512135A (en) 2001-08-21
PL338373A1 (en) 2000-10-23

Similar Documents

Publication Publication Date Title
HUP0002495A1 (en) Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
HUP0003921A2 (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
HUP0004259A2 (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof
HUP0002682A1 (en) Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
HUP0004529A2 (en) Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
HUP0202381A2 (en) Method for treating chronic pain using mek inhibitors
HUP9700602A1 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
HUP0301249A2 (en) Benzamide compounds as apo b secretion inhibitors pharmaceutical compositions containing them and their use
HUP0004531A2 (en) 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
HUP0104867A2 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0002476A2 (en) Amine compounds, their production and use
HUP0002272A2 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
MXPA06001274A (en) Novel compounds having inhibitory activity against sodium-dependant transporter.
HUP0102563A2 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
HUP0100669A2 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
ATE103812T1 (en) COMPOSITION FOR THE TREATMENT OF ISCHEMIC DISORDERS IN ORGANS.
HUP9802937A2 (en) Benzo[g]quuinoline derivatives, pharmaceutical compositions containing them and their use
EP0671390A3 (en) Antithrombotic agents
NO961000L (en) Piperidine derivatives, process for their preparation and drug and preparation containing them
ES2101073T3 (en) NEW AZA-ANDROSTANO-DERIVATIVES 17-BETA-SUBSTITUTED.
ES2073258T3 (en) NEW DERIVATIVES OF THE UREA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
TR199801614T2 (en) Peptide derivatives
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
HUP0102025A2 (en) Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
TW324007B (en) N-substituted diazabicycloheptane derivative and its pharmaceutical use